Contract research organisation (CRO) BioPharmaSpec has committed to building three new European facilities.
The novel sites will be focused on drug discovery and R&D services for the biopharmaceutical market, as welll as offering structural and physicochemical characterisation services.
The company can assist clients in discovering and developing monoclonal antibodies, antibody-drug conjugates (ADCs) therapeutic peptides, cell and gene therapies and oligonucleotides.
BioPharmaSpec will also be able to offer HCP identification, as well as quantification services relating to product and process shortcomings.
The novel laboratories situated in Germany, Italy and Lithuania will also contain the latest instrumentation, including:
- Waters Select Series CYCLIC Ion Mobility Separation (IMS) High Definition LC-MS/MS with ECD
- SCIEX ZenoTOF 7600 LC-MS/MS with EAD
- Waters Xevo TQ Absolute
- Waters Xevo G3 LC-MS/MS Q-TOFs
According to the company, this equipment will allow it to rapidly perform structural characterisation of potential biopharmaceuticals for clients across the globe.
Founder of BioPharmaSpec group, Prof. Howard Morris, commented: "Complementing a long career in academia where I’ve been the Professor of Biological Chemistry at Imperial College since 1980 it has been a privilege to help drive forward this exciting development and significant expansion of BioPharmaSpec."
"The Freiburg, Bergamo and Vilnius sites join our existing UK and US-based facilities to create the BioPharmaSpec Group of companies, serving the global biopharmaceutical industry”
“With the opening of these new laboratories in January 2025 and recruitment of local expert scientists, we are strategically and uniquely placed to provide our expanding global client base with the highest levels of technical and customer service." said Director of Business Development, Lindsay McGowan.